Glenmark has cut the price of COVID-19 drug by 27% to Rs.75 per tablet, which had been originally priced at Rs.103 per tablet. Glenmark had received approval from the DCGI to launch generic version of Favipravir, which has launched under the name of FabiFlu. The price reduction was announced by Glenmark to make the medication more accessible.

The impact on the performance of the company or its price performance may not be very meaningful. The FabiFlu generic version of Favipravir can be only used to treat very mild symptoms of COVID-19. Glenmark has already completed Phase-3 trials on mild to moderate infected patients and trial results are expected shortly. Impact could be limited.